Vyome Holdings, Inc. a clinical-stage healthcare holding company, announced Dr. Aditya Bardia as Senior Medical Advisor to Vyome. In this consulting role, Dr. Bardia will guide the clinical development of Vyome’s lead asset, VT-1953, for the treatment of symptoms of malignant fungating wounds (MFW), a debilitating condition in cancer patients for which approval is being targeted in 2026.
Health Technology Insights: Hallmark Health Forms Executive Advisory Board
“I am excited to work with Vyome team and guide the clinical development of VT-1953 for the treatment of symptoms of malignant fungating wound, a debilitating condition that can significantly impair quality of life for patients with cancer,” said Dr. Bardia. “In my clinical practice, I have seen patients suffer from this horrible condition, and we really need an effective treatment for this major unmet clinical need. I am encouraged by the preliminary data with VT-1953 in MFW, and the mechanistic basis for this therapy. This is the perfect opportunity to develop a first-in-class therapy, which can improve the quality of life for patients with cancer.”
Health Technology Insights: TestDynamics Launches Unified Medical Imaging AI System
Dr. Bardia has led clinical trials that have resulted in many drug approvals, including Sacituzumab Govitecan, Trastuzumab Deruxtecan, and Datopotamab Deruxtecan, which became blockbuster drugs. Dr. Bardia also led the clinical development of Elacestrant, the first oral SERD approved for patients with metastatic HR+ positive breast cancer. Trained at Johns Hopkins in medical oncology, Dr. Bardia joined Massachusetts General Hospital-Harvard Medical School as a faculty member before moving to David Geffen School of Medicine at UCLA and the UCLA Health Jonsson Comprehensive Cancer Center as Professor and director of the Breast Cancer Program and Translational Research Integration. He has also received numerous awards and honors.
“Dr. Bardia’s expertise in having led the development of multiple drugs and especially steering them through accelerated FDA approvals aligns with our strategy of designing robust, but cost-efficient, trials,” said Dr. Shiladitya Sengupta, Associate Professor of Medicine, Harvard Medical School, and Co-Founder of Vyome. “We are delighted that Dr. Bardia decided to work with the Vyome team, significantly bolstering our depth in developing next-generation therapies, as we embark on pivotal studies with our lead asset.”
“The collaboration with Dr. Bardia marks an important milestone in Vyome’s growth journey. We have a brilliant team in place to unlock the next milestones of value in our lead program,” said Venkat Nelabhotla, CEO of Vyome.
Health Technology Insights: IKS Health Appoints New Chief Marketing and Chief Legal and Compliance Officers
To participate in our interviews, please write to our HealthTech Media Room at info@intentamplify.com
Source- businesswire
